These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 30738982)

  • 21. Bioactivation antioxidant and transglycating properties of N-acetylcarnosine autoinduction prodrug of a dipeptide L-carnosine in mucoadhesive drug delivery eye-drop formulation: powerful eye health application technique and therapeutic platform.
    Babizhayev MA
    Drug Test Anal; 2012 Jun; 4(6):468-85. PubMed ID: 21416634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Turning the screw even further to increase microparticle retention and ocular bioavailability of associated drugs: The bioadhesion goal.
    Rodríguez Villanueva J; Rodríguez Villanueva L
    Int J Pharm; 2017 Oct; 531(1):167-178. PubMed ID: 28822703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of ocular drug delivery systems using molecularly imprinted soft contact lenses.
    Tashakori-Sabzevar F; Mohajeri SA
    Drug Dev Ind Pharm; 2015 May; 41(5):703-13. PubMed ID: 25113431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physiologically based ocular pharmacokinetic modeling using computational methods.
    Missel PJ; Sarangapani R
    Drug Discov Today; 2019 Aug; 24(8):1551-1563. PubMed ID: 31319151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel drug delivery systems for ocular therapy: With special reference to liposomal ocular delivery.
    Bhattacharjee A; Das PJ; Adhikari P; Marbaniang D; Pal P; Ray S; Mazumder B
    Eur J Ophthalmol; 2019 Jan; 29(1):113-126. PubMed ID: 29756507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances in ocular drug delivery.
    Achouri D; Alhanout K; Piccerelle P; Andrieu V
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1599-617. PubMed ID: 23153114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ophthalmic drug delivery systems--recent advances.
    Bourlais CL; Acar L; Zia H; Sado PA; Needham T; Leverge R
    Prog Retin Eye Res; 1998 Jan; 17(1):33-58. PubMed ID: 9537794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ocular drug delivery-eye on innovation.
    Rupenthal ID; O'Rourke M
    Drug Deliv Transl Res; 2016 Dec; 6(6):631-633. PubMed ID: 27766597
    [No Abstract]   [Full Text] [Related]  

  • 29. Drug Delivery for Ocular Allergy: Current Formulation Design Strategies and Future Perspectives.
    Regu VR; Swain RP; Subudhi BB
    Curr Pharm Des; 2023; 29(33):2626-2639. PubMed ID: 37936454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ocular biopharmaceutics: impact of modeling and simulation on topical ophthalmic formulation development.
    Gukasyan HJ; Hailu S; Karami TK; Graham R
    Drug Discov Today; 2019 Aug; 24(8):1587-1597. PubMed ID: 30959112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ocular tissue distribution and pharmacokinetic study of a small 13kDa domain antibody after intravitreal, subconjuctival and eye drop administration in rabbits.
    Gough G; Szapacs M; Shah T; Clements P; Struble C; Wilson R
    Exp Eye Res; 2018 Feb; 167():14-17. PubMed ID: 29074387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advance of the application of nano-controlled release system in ophthalmic drug delivery.
    Wang X; Wang S; Zhang Y
    Drug Deliv; 2016 Oct; 23(8):2897-2901. PubMed ID: 26635087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fundamentals, challenges, and nanomedicine-based solutions for ocular diseases.
    Srinivasarao DA; Lohiya G; Katti DS
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jul; 11(4):e1548. PubMed ID: 30506871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review on therapeutic contact lenses for ocular drug delivery.
    Maulvi FA; Soni TG; Shah DO
    Drug Deliv; 2016 Oct; 23(8):3017-3026. PubMed ID: 26821766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contact lenses: promising devices for ocular drug delivery.
    Guzman-Aranguez A; Colligris B; Pintor J
    J Ocul Pharmacol Ther; 2013 Mar; 29(2):189-99. PubMed ID: 23215541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The gap between the need for novel retinal drug delivery methods, technologies in R&D phase, and approved ocular drug delivery technologies.
    Neumann R; Barequet D
    Drug Discov Today; 2019 Aug; 24(8):1433-1435. PubMed ID: 30904724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Ocular pharmacokinetics: Topical, intravitreal, and systemic drug application].
    Meyer CH; Krohne TU
    Ophthalmologe; 2014 Feb; 111(2):104-6. PubMed ID: 24510172
    [No Abstract]   [Full Text] [Related]  

  • 38. Topical ocular drug delivery systems: Innovations for an unmet need.
    Yang Y; Lockwood A
    Exp Eye Res; 2022 May; 218():109006. PubMed ID: 35248559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Comprehensive Review on the Role of Polymers in Ocular Drug Delivery.
    Paramjot ; Wadhwa S; Sharma A; Singh SK; Vishwas S; Kumar R; Singh S; Dua K; Chellappan DK; Gupta G
    Curr Drug Deliv; 2024; 21(1):16-37. PubMed ID: 36627785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent patents on ocular drug delivery systems.
    Conway BR
    Recent Pat Drug Deliv Formul; 2008; 2(1):1-8. PubMed ID: 19075892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.